Vapiprost | CAS#85505-64-2 | thromboxane receptor antagonist

MedKoo Cat#: 584415 | Name: Vapiprost

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Vapiprost is a thromboxane receptor antagonist and prostaglandin receptor antagonist.

Chemical Structure

Vapiprost

CAS#85505-64-2

Theoretical Analysis

MedKoo Cat#: 584415

Name: Vapiprost

CAS#: 85505-64-2

Chemical Formula: C30H39NO4

Exact Mass: 477.2879

Molecular Weight: 477.65

Elemental Analysis: C, 75.44; H, 8.23; N, 2.93; O, 13.40

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

Vapiprost; GR 32191; GR32191; GR-32191

IUPAC/Chemical Name

4-Heptenoic acid, 7-(5-((1,1'-biphenyl)-4-ylmethoxy)-3-hydroxy-2-(1-piperidinyl)cyclopentyl)-, (1R-(1alpha(Z),2beta,3beta,5alpha))-

InChi Key

GQGRDYWMOPRROR-XUSMOFMBSA-N

InChi Code

InChI=1S/C30H39NO4/c32-27-21-28(35-22-23-15-17-25(18-16-23)24-11-5-3-6-12-24)26(13-7-1-2-8-14-29(33)34)30(27)31-19-9-4-10-20-31/h1-3,5-6,11-12,15-18,26-28,30,32H,4,7-10,13-14,19-22H2,(H,33,34)/b2-1-/t26-,27-,28-,30+/m0/s1

SMILES Code

O=C(O)CC/C=C\CC[C@@H]1[C@@H](N2CCCCC2)[C@@H](O)C[C@@H]1OCC3=CC=C(C4=CC=CC=C4)C=C3

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 477.65 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Uematsu T, Nagashima S, Mizuno A, Hirano K, Nakashima M. Pharmacokinetic and pharmacodynamic profiles of vapiprost, a selective, long-lasting thromboxane receptor antagonist, after single and multiple oral administration to healthy volunteers. J Clin Pharmacol. 1991 Sep;31(9):815-22. PubMed PMID: 1839540. 2: Nishiyama H, Umemura K, Saniabadi AR, Takiguchi Y, Uematsu T, Nakashima M. Enhancement of thrombolytic efficacy of tissue-type plasminogen activator by adjuvants in the guinea pig thrombosis model. Eur J Pharmacol. 1994 Oct 24;264(2):191-8. PubMed PMID: 7851482. 3: Kan KK, Jones RL, Ngan MP, Rudd JA. Action of prostanoids on the emetic reflex of Suncus murinus (the house musk shrew). Eur J Pharmacol. 2003 Sep 23;477(3):247-51. PubMed PMID: 14522363. 4: Matsuzaki T, Noguchi K, Nakasone J, Uezu K, Higuchi M, Sakanashi M. Effects of the new thromboxane A2 antagonist vapiprost on isolated canine blood vessels. Arzneimittelforschung. 1992 Nov;42(11):1318-22. PubMed PMID: 1492844. 5: Idris-Khodja N, Auger C, Koch E, Schini-Kerth VB. Crataegus special extract WS(®)1442 prevents aging-related endothelial dysfunction. Phytomedicine. 2012 Jun 15;19(8-9):699-706. doi: 10.1016/j.phymed.2012.04.005. Epub 2012 May 22. PubMed PMID: 22621780. 6: Carter PR, McElhatten RM, Zhang S, Wright WS, Harris NR. Thromboxane-prostanoid receptor expression and antagonism in dextran-sodium sulfate-induced colitis. Inflamm Res. 2011 Jan;60(1):87-92. doi: 10.1007/s00011-010-0240-2. Epub 2010 Aug 8. PubMed PMID: 20694740. 7: Sakanashi M, Matsuzaki T, Noguchi K, Nakasone J, Itomine T, Uza M, Toyama F, Higuchi M. Inhibitory effect of vapiprost on contractile responses of isolated dog renal arteries to thromboxane A2 analogue, U46619. Gen Pharmacol. 1994 Jul;25(4):617-22. PubMed PMID: 7958719. 8: Exner HJ, Schlicker E. Prostanoid receptors of the EP3 subtype mediate the inhibitory effect of prostaglandin E2 on noradrenaline release in the mouse brain cortex. Naunyn Schmiedebergs Arch Pharmacol. 1995 Jan;351(1):46-52. PubMed PMID: 7715741. 9: Umemura K, Asai Y, Uematsu T, Nakashima M. Role of thromboxane A2 in a microcirculation disorder of the rat inner ear. Eur Arch Otorhinolaryngol. 1993;250(6):342-4. PubMed PMID: 8260145. 10: Umemura K, Kawai H, Ishihara H, Nakashima M. Inhibitory effect of clopidogrel, vapiprost and argatroban on the middle cerebral artery thrombosis in the rat. Jpn J Pharmacol. 1995 Mar;67(3):253-8. PubMed PMID: 7630043. 11: Tsui SS, Kirshbom PM, Davies MJ, Jacobs MT, Kern FH, Gaynor JW, Greeley WJ, Ungerleider RM. Thromboxane A2-receptor blockade improves cerebral protection for deep hypothermic circulatory arrest. Eur J Cardiothorac Surg. 1997 Aug;12(2):228-35. PubMed PMID: 9288512. 12: Ohashi K, Aso R. Influence of age on the pharmacokinetics of vapiprost, a thromboxane A2 receptor antagonist, and platelet aggregation: comparison of pharmacokinetics by routine approach and population pharmacokinetics. Int J Clin Pharmacol Res. 2001;21(2):85-94. PubMed PMID: 11824652. 13: White BP, Sullivan AT, Lumley P. Prevention of intra-coronary thrombosis in the anaesthetised dog: the importance of thromboxane A2 and thrombin. Thromb Haemost. 1994 Mar;71(3):366-74. PubMed PMID: 8029802. 14: Hirata Y, Umemura K, Uematsu T, Nakashima M. An experimental myocardial infarction model in the rat and its properties. Jpn J Pharmacol. 1995 Jan;67(1):51-7. PubMed PMID: 7745845. 15: Lundell A, Bergqvist D, Leide S, Lindblad B, Ljungberg J. The effect of a thromboxane receptor antagonist on acute ePTFE arterial graft thrombogenicity--an experimental study in sheep. Eur J Vasc Surg. 1991 Jun;5(3):321-6. PubMed PMID: 1830856. 16: Takiguchi Y, Hirata Y, Wada K, Nakashima M. Arterial thrombosis model with photochemical reaction in guinea-pig and its property. Thromb Res. 1992 Aug 15;67(4):435-45. PubMed PMID: 1412222. 17: Takiguchi Y, Wada K, Nakashima M. Comparison of the inhibitory effects of the TXA2 receptor antagonist, vapiprost, and other antiplatelet drugs on arterial thrombosis in rats: possible role of TXA2. Thromb Haemost. 1992 Oct 5;68(4):460-3. PubMed PMID: 1448780. 18: Matsuno H, Uematsu T, Umemura K, Takiguchi Y, Wada K, Nakashima M. Effects of vapiprost, a novel thromboxane receptor antagonist, on thrombus formation and vascular patency after thrombolysis by tissue-type plasminogen activator. Br J Pharmacol. 1992 Jul;106(3):533-8. PubMed PMID: 1387025; PubMed Central PMCID: PMC1907568. 19: Takiguchi Y, Asai F, Wada K, Nakashima M. Comparison of antithrombotic effects of GPIIb-IIIa receptor antagonist and TXA2 receptor antagonist in the guinea-pig thrombosis model: possible role of TXA2 in reocclusion after thrombolysis. Thromb Haemost. 1995 Apr;73(4):683-8. PubMed PMID: 7495079. 20: Kawano KI, Hokamura K, Kondo K, Ikeda Y, Suzuki Y, Umemura K. Thromboxane A(2) synthase inhibitor enhanced antithrombotic efficacy of GPIIb-IIIa receptor antagonist without increasing bleeding. Eur J Pharmacol. 2001 Apr 13;417(3):217-22. PubMed PMID: 11334853.